Overview
Cortexin is a polypeptide preparation extracted from the cerebral cortex of cattle, developed in part by the Khavinson research group and registered as a pharmaceutical drug in Russia since 1999. It is approved in Russia and several Eastern European countries for treatment of stroke, traumatic brain injury, and cognitive impairment. It contains low-molecular-weight water-soluble polypeptide fractions (1,000–10,000 Da) that cross the blood-brain barrier.
Mechanism of action
Cortexin contains a complex mixture of polypeptides, amino acids, and trace elements from bovine cerebral cortex that cross the blood-brain barrier and directly interact with neuronal cells. Its neuroprotective mechanism involves regulating the balance between excitatory (glutamatergic) and inhibitory (GABAergic) neurotransmitters, modulating dopamine and serotonin signaling, and reducing paroxysmal seizure activity. At the molecular level, Cortexin peptides interact with neuron-specific proteins including β5-tubulin, creatine kinase B, and protein 14-3-3 α/β, engaging pathways governing signal transduction, energy metabolism, proteolytic protein modification, cell structure, and neuroinflammation. These multi-target actions promote neuroplasticity and neuroprotection after ischemic or traumatic injury. The preparation also reduces oxidative stress in neuronal tissue and supports neurotrophic factor activity.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| neuroprotection / cognitive research | intramuscular | 10–10 mg | daily for 10 days | Standard Russian clinical protocol: 10 mg IM daily for 10 days. Reconstitute in 1–2 mL sterile saline. Courses repeated 2–3 times per year. Pediatric dosing uses 5 mg. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Cortexin has been studied in Russian and international clinical trials for ischemic stroke, TBI, and cognitive impairment. Comparative studies show neuroprotective effects comparable to Cerebrolysin and Actovegin in acute brain ischemia models. A 2021 PMC-indexed study demonstrated significantly reduced cortical neuron loss in rat cerebral ischemia models. Clinical use in Russia spans over 25 years with documented efficacy in stroke recovery programs. A Cochrane-level systematic review does not exist for Cortexin specifically; evidence quality by Western standards remains moderate. It is approved by the Russian Ministry of Health for neurological conditions.
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Cortexin for synergistic effects.
Legal status
Registered pharmaceutical drug approved in Russia (1999) and several Eastern European countries. Not FDA-approved. Available in Western markets only as a research substance. Not approved for therapeutic human use in the US or EU. Comparable to Cerebrolysin in regulatory status.
Where to get it
Verified directory — coming soon
PeptaHub is building a verified supplier directory with third-party testing data, compliance status, and reader ratings.